Compare · ADGM vs BSX
ADGM vs BSX
Side-by-side comparison of Adagio Medical Holdings Inc (ADGM) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADGM and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.44B, about 5559.5x ADGM ($11.8M).
- Over the past year, ADGM is down 65.9% and BSX is down 57.6% - BSX leads by 8.3 points.
- Both names hit the wire about 1 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 2 for ADGM).
- Company
- Adagio Medical Holdings Inc
- Boston Scientific Corporation
- Price
- $0.52-1.02%
- $44.02-1.32%
- Market cap
- $11.8M
- $65.44B
- 1M return
- -28.82%
- -6.16%
- 1Y return
- -65.93%
- -57.59%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 1
- Recent ratings
- 2
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest ADGM
- Amendment: SEC Form 10-K/A filed by Adagio Medical Holdings Inc
- Adagio Medical Holdings Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Adagio Medical Holdings Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Adagio Medical Holdings Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
- Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc
- Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc
- SEC Form 10-Q filed by Adagio Medical Holdings Inc
- Adagio Medical Holdings Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form DEF 14A filed by Adagio Medical Holdings Inc
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints